The COVID‐19 pandemic has impacted negatively on health and the economy worldwide in an unprecedented manner and scale. Men appear to be disproportionately affected, with male deaths outnumbering those of women on average by two to one. Both sexes have variable outcomes, but those with pre‐existing cardiovascular disease (CVD), hypertension and diabetes, appear to do disproportionately worse. The high infectivity of the SARS‐CoV‐2 virus is in part related to new mutations in the receptor binding domain, and the acquisition of a furin cleavage site in the S spike protein. The continued viral shedding in asymptomatic and presymptomatic individuals enhances its community transmission, resulting an R value of around 3 (that is, one affected individual on average transmits the disease to three other people, in the absence of social distancing).

Transmission occurs when the virus uses the ACE2 receptor for internalisation into airway cells, aided by TMPRSS2 protease, and the ACE2 receptor is expressed more strongly in airways of men compared with women. The tissue localisation of these receptors correlates with COVID‐19 symptoms and organ dysfunction. Virus‐induced ACE2 down regulation may attenuate its function, diminish its anti‐inflammatory role, and result in heightened angiotensin II effects in predisposed patients.

Lymphopenia occurs early and is prognostic, potentially associated with reduction of the CD4+ and some CD8+ T cells. This leads to imbalance of the innate/acquired immune response, delayed viral clearance, and hyperstimulated macrophages and neutrophils. Persistent immune activation in predisposed patients, especially the elderly and those with CV risk, can create uncontrolled cytokine production, the so‐called 'cytokine storm', resulting in multi‐organ failure and death.

In addition to the characteristic inflammation in the airways and lungs, the CV system is often involved in COVID‐19 illness, reflected in the release of highly sensitive troponin and natriuretic peptides, which are all prognostic, particularly in those showing continued rise, along with cytokines such as IL‐6. Men are more susceptible to CVD than women. Inflammation in the vascular system can result in diffuse microangiopathy with thrombosis. Inflammation in the myocardium can result in myocarditis, heart failure, cardiac arrhythmias, acute coronary syndrome, rapid deterioration and sudden death.

Aggressive support based on early prognostic indicators can potentially improve recovery. As well as ventilatory support, appropriate treatment for heart failure, arrhythmias, acute coronary syndrome and thrombosis are important. Specific evidence‐based treatment strategies for COVID‐19 are likely to emerge from ongoing randomised controlled trials.

As in so many other conditions, the reluctance of men to report their symptoms may result in a delay in their presentation. Men also smoke more heavily and longer than women, and are also more likely to suffer from chronic obstructive airways disease. To protect the wider population, women as well as men, antibody testing to confirm immunity and an effective vaccine will be needed if we are ever to consign COVID‐19 to the history books.
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